Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Shares of Palo Alto Networks (NASDAQ:PANW) fell more than 2% in premarket trading Wednesday after analysts at BTIG and ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

BTIG analyst Gray Powell downgraded Palo Alto Networks (PANW) to Neutral from Buy without a price target After reviewing Palo Alto’s share in ...

Short seller Hindenburg Research accused Carvana of accounting manipulation and unstable loans. The company denies the ...

On Wednesday, Nuvation Bio Inc (NUVB) stock saw a decline, ending the day at $3.01 which represents a decrease of $-0.24 or -7.38% from the prior close of $3.25. The stock opened at $3.32 and touched ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.

BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...